Moreover, in a recent paper, we observed that the in vivo direct irreversible inhibition of NLRP3 with INF39, a novel acrylate compound able to inhibit NLRP3 ATPase activity, exerts beneficial effects on bowel inflammation (Cocco et al., 2017). Here, NLRP3 is linked to inflammatory response.